Moleculin Biotech (MBRX) Earnings Date & Reports

Moleculin Biotech Inc is a late-stage pharmaceutical development company currently evaluating Annamycin, also known as L-Annamycin and by its generic name naxtarubicin... Show more

Industry: #Pharmaceuticals Major

Get AI intraday signals

A.I. Advisor

published Earnings

MBRX is expected to report earnings to fall 122.32% to -153 cents per share on August 19

Moleculin Biotech MBRX Stock Earnings Reports

Q2'26

Est.

$-1.54

Q4'25

Beat

by $8.15

Q3'25

Beat

by $0.57

Q2'25

Beat

by $0.76

Q4'23

Missed

by $1.79

The last earnings report on March 18 showed earnings per share of $6.90, beating the estimate of -125 cents. With 802.28K shares outstanding, the current market capitalization sits at 16.57M.

View a ticker or compare two or three

Compare

MBRX

Setup

Daily Signal:

Description

Gain/Loss:

Interact to see
Advertisement

A.I.Advisor

published price charts

Last 5 trading days

View AI-Driven Trading for MBRX